#1 Clinical Trials Search in Europe

Acp-017

TransCon TLR7/8 Agonist, also known as ACP-017, is an innovative drug being studied in clinical trials for various advanced or metastatic solid tumors. This article explores the ongoing research on ACP-017, its potential benefits, and its role in combination with other cancer treatments, offering hope for patients with difficult-to-treat cancers.

Table of Contents

What is ACP-017?

ACP-017, also known as TransCon TLR7/8 Agonist, is a new cancer treatment currently being studied in clinical trials[1]. It is a type of drug called a TLR7/8 agonist, which means it activates specific receptors in the immune system called Toll-like receptor 7 and 8[2]. ACP-017 is being developed by Ascendis Pharma as a potential treatment for various types of cancer.

How does ACP-017 work?

ACP-017 works by stimulating the immune system to fight cancer cells. When injected directly into tumors, it activates TLR7 and TLR8 receptors, which triggers an immune response against the cancer[3]. This immune activation can potentially help the body recognize and attack cancer cells more effectively. ACP-017 is often studied in combination with other cancer treatments, such as pembrolizumab, which is an immunotherapy drug that helps the immune system fight cancer in a different way[1].

What types of cancer is ACP-017 being studied for?

ACP-017 is being investigated for several types of cancer, including:

  • Head and neck squamous cell carcinoma (HNSCC)[1]
  • Melanoma (a type of skin cancer)[3]
  • Non-small cell lung cancer (NSCLC)[2]
  • Small cell lung cancer (SCLC)[2]
  • Ovarian cancer[2]
  • Cervical cancer[2]
  • Other HPV-associated cancers (such as anal, vulvar, penile, or vaginal cancers)[3]
  • Cutaneous squamous cell carcinoma (a type of skin cancer)[3]

How is ACP-017 administered?

ACP-017 is administered through intratumoral (IT) injection, which means it is injected directly into the tumor[1]. The dosing schedule can vary depending on the specific clinical trial and treatment plan. Some common dosing schedules being studied include:

  • Every 6 weeks (Q6W)[3]
  • Every 3 weeks (Q3W) for a certain number of treatments, followed by a response-dependent schedule[3]

In some trials, ACP-017 is given in combination with other cancer treatments, such as pembrolizumab, which is administered intravenously (IV)[3].

What are the potential benefits of ACP-017?

The potential benefits of ACP-017 include:

  • Enhanced immune response against cancer: By activating TLR7 and TLR8 receptors, ACP-017 may help stimulate a stronger immune response against cancer cells[2].
  • Targeted treatment: Because it is injected directly into tumors, ACP-017 may provide a more targeted approach to treating cancer[3].
  • Potential for combination therapy: ACP-017 is being studied in combination with other cancer treatments, which may lead to improved outcomes for patients[1].
  • Possible treatment for various cancer types: ACP-017 is being investigated for multiple types of cancer, which could potentially benefit a wide range of patients[2].

What are the side effects and risks of ACP-017?

As ACP-017 is still in clinical trials, the full range of side effects and risks is not yet known. However, some potential side effects and risks may include:

  • Immune-related side effects: Since ACP-017 stimulates the immune system, it may cause immune-related side effects similar to other immunotherapy treatments[3].
  • Injection site reactions: As the drug is injected directly into tumors, there may be local reactions at the injection site[3].
  • Fatigue: This is a common side effect of many cancer treatments[2].
  • Potential for autoimmune reactions: Patients with active autoimmune conditions are typically excluded from clinical trials, suggesting a potential risk for autoimmune reactions[3].

It’s important to note that the safety profile of ACP-017 is still being evaluated in clinical trials, and patients should discuss potential risks and side effects with their healthcare providers.

Current clinical trials for ACP-017

Several clinical trials are currently ongoing to evaluate the safety and effectiveness of ACP-017. Some of these trials include:

  • A Phase 2 trial studying ACP-017 in combination with pembrolizumab for patients with advanced head and neck cancer[1].
  • A Phase 1/2 trial investigating ACP-017 alone or in combination with pembrolizumab for patients with various advanced or metastatic solid tumors[2].
  • A Phase 1/2 trial studying ACP-017 with or without pembrolizumab in patients with advanced or metastatic solid tumors, including a focus on neoadjuvant treatment for melanoma and cutaneous squamous cell carcinoma[3].

Conclusion

ACP-017 (TransCon TLR7/8 Agonist) is a promising new cancer treatment that works by stimulating the immune system to fight cancer cells. It is currently being studied for various types of cancer, including head and neck cancer, melanoma, lung cancer, and other solid tumors. While the potential benefits of ACP-017 are encouraging, it’s important to remember that the drug is still in clinical trials, and more research is needed to fully understand its effectiveness and safety profile. Patients interested in ACP-017 should discuss their options with their healthcare providers and consider participating in clinical trials if appropriate.

Aspect Details
Drug Name TransCon TLR7/8 Agonist (ACP-017)
Administration Intratumoral (IT) injection
Cancer Types Studied Advanced solid tumors, head and neck cancer, melanoma, cervical cancer, breast cancer, HPV-associated cancers
Combination Therapies Pembrolizumab, standard chemotherapy
Key Objectives Evaluate safety, tolerability, determine optimal dosing, assess anti-tumor activity
Notable Endpoints Objective response rate, pathologic complete response, major pathologic response, progression-free survival, overall survival
Trial Phases Phase 1/2 studies, including dose escalation and expansion cohorts

FAQ

  • What is TransCon TLR7/8 Agonist (ACP-017)? TransCon TLR7/8 Agonist (ACP-017) is an experimental drug that stimulates the immune system to fight cancer. It is being tested in clinical trials for patients with advanced or metastatic solid tumors.
  • How is ACP-017 administered? ACP-017 is typically administered through intratumoral (IT) injection, which means it is injected directly into the tumor. The frequency of administration varies depending on the specific trial and treatment plan.
  • What types of cancer is ACP-017 being studied for? ACP-017 is being investigated for various solid tumors, including head and neck cancer, melanoma, cervical cancer, breast cancer, and other HPV-associated cancers.
  • Is ACP-017 used alone or in combination with other treatments? ACP-017 is being studied both as a standalone treatment and in combination with other cancer therapies, such as pembrolizumab (an immunotherapy drug) and standard chemotherapy.
  • What are the potential benefits of ACP-017? Early studies suggest that ACP-017 may help stimulate the immune system to fight cancer more effectively. It is being investigated for its potential to improve response rates, extend survival, and provide new options for patients who have not responded to other treatments.

Ongoing Clinical Trials on Acp-017

  • Study of ACP-017 and Pembrolizumab for Patients with Advanced or Metastatic Cancer

    Not recruiting

    2 1 1 1
    Investigated drugs:
    The Netherlands Spain

  • Study of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and Pembrolizumab for Patients with Advanced Head and Neck Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Hungary Italy Poland Spain

  • Study on the Safety and Tolerability of TransCon IL-2 β/γ, Pembrolizumab, and Chemotherapy in Adults with Advanced or Metastatic Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Italy Poland Spain

Glossary

  • Intratumoral (IT): A method of administering medication directly into a tumor.
  • Pembrolizumab: An immunotherapy drug that helps the immune system detect and fight cancer cells.
  • Neoadjuvant therapy: Treatment given before the main treatment, usually to shrink a tumor before surgery.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Pathologic complete response (pCR): The absence of all signs of cancer in tissue samples removed during surgery or biopsy after treatment.
  • Major pathologic response (MPR): A significant reduction in cancer cells found in tissue samples after treatment, but not a complete disappearance.
  • Dose-limiting toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or level of use.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that does not cause unacceptable side effects.
  • Recommended Phase 2 Dose (RP2D): The dose of a drug recommended for further testing in larger clinical trials based on safety and early efficacy data.
  • HPV: Human Papillomavirus, a virus that can cause certain types of cancer.

References

  1. http://clinicaltrials.eu/trial/study-of-transcon-tlr7-8-agonist-transcon-il-2-%ce%b2-%ce%b3-and-pembrolizumab-for-patients-with-advanced-head-and-neck-cancer/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-transcon-il-2-%ce%b2-%ce%b3-pembrolizumab-and-chemotherapy-in-adults-with-advanced-or-metastatic-solid-tumors/
  3. http://clinicaltrials.eu/trial/study-of-acp-017-and-pembrolizumab-for-patients-with-advanced-or-metastatic-cancer/